Xcenda Presents Co-Authored Posters at 16th International Myeloma Workshop

February 28, 2017

Company News

Xcenda is proud to co-present recent research and findings at the 16th International Myeloma Workshop.

New Delhi, India | March 1-4, 2017

Poster #T-145

Association Between Treatment Regimen Type in Second-line Therapy and Duration of Therapy and Time to Next Treatment in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort

Poster #T-146

Newly Diagnosed Multiple Myeloma (NDMM): Effect of Age, Renal Insufficiency, and Cardiovascular Disease on Overall Survival and Treatment Patterns Among Stem Cell Transplant-ineligible Patients in the United States (US)

Poster #T-144

Treatment Patterns and Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-ineligible Patients with Multiple Myeloma in the Era of Novel Agents

Poster #T-143

Triplet Therapy and Overall Survival in Routine Practice Among Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM) in the United States (US)

Poster #F-209

Predictors of Treatment With First-line Therapy Among Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM) in Routine Clinical Care